Welcome to our dedicated page for Trendlines news (Ticker: TRNGF), a resource for investors and traders seeking the latest updates and insights on Trendlines stock.
The Trendlines Group Ltd. (TRNGF) is associated with The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), which appears in multiple portfolio company announcements as an investment group focused on early-stage medical technology and life sciences ventures. News related to The Trendlines Group often comes through updates from its portfolio companies, providing insight into the progress of medical device and healthcare technology innovations that Trendlines supports.
Investors and observers following TRNGF can use this news feed to monitor milestones achieved by portfolio companies that cite The Trendlines Group as an investor or incubator. Recent announcements include funding rounds, regulatory clearances, and clinical achievements by companies such as Escala Medical Ltd., Arcuro Medical Ltd., Limaca Medical Ltd., Vensica Medical, ZygoFix Ltd., Fidmi Medical Ltd., Vessi Medical, Dasyo, and Ceretrieve, all of which reference The Trendlines Group in their disclosures.
Typical news items include FDA clearances for new medical devices, clinical study results in areas such as ischemic stroke and bladder cancer, funding rounds to advance commercialization or clinical trials, and strategic appointments at portfolio companies. These developments highlight the types of innovations and regulatory milestones that can influence the value and outlook of an investment group focused on MedTech and life sciences.
By reviewing this page regularly, users can track how The Trendlines Group’s portfolio evolves over time through public announcements from its investee companies, gaining a clearer picture of the themes, technologies, and therapeutic areas that shape the company’s exposure within the healthcare and medical technology landscape.
NICE Surgical Solutions, a clinical-stage medical device company, has been granted U.S. Patent No. 12,661,097 B2 for an extracting device used with its purse-string stapler, designed to generally eliminate surgical incisions in colorectal surgery by enabling tissue extraction through the intra-anal canal.
The patent covers the extraction device and its introducer, which, together with NICE Surgical's existing patented purse-string stapler, allows colorectal procedures and tissue retrieval to be performed fully intracorporeally and minimally invasively. NICE Surgical is a portfolio company of Trendlines Medical Singapore, a subsidiary of The Trendlines Group (OTCQX: TRNLY, TRNGF), an investment company focused on medtech and agrifood innovation.
NICE Surgical Solutions, a clinical-stage medtech company, has been granted U.S. Patent No. 12,653,527 B2 for its purse-string stapler for colorectal surgery. The device enables intracorporeal purse-string suturing, stapling, and resection, targeting full intracorporeal anastomosis.
The patented technology is designed to complete colorectal procedures minimally invasively, without an abdominal incision, which may improve efficiency and reduce surgical site infections. NICE Surgical is a portfolio company of Trendlines (TRNGF). Human clinical studies are planned by Q4 2026.
IBI Ag (OTC:TRNGF) announced on March 10, 2026 completion of a proof of concept for an AI-driven de novo protein design platform for bioinsecticides. The POC produced novel proteins validated in insect bioassays, showing efficacy against key agricultural pests and enabling greenhouse and field trial plans.
The platform leverages proprietary biological data and IP to target pests selectively, aiming to reduce impact on beneficial insects while improving stability, shelf life, and production economics.
Escala Medical Ltd., a FemTech medical device company specializing in women's health solutions, has secured $4.5 million in funding to accelerate the global expansion of its FDA-approved device for Pelvic Organ Prolapse (POP) treatment.
The funding round includes investment from the EIC Fund, following a €2.5 million grant awarded through the EIC Accelerator program in October 2023, along with participation from private investors in the United States and Israel. The company's flagship Mendit device, which received FDA approval and was commercially launched in 2023, has already been used in hundreds of successful procedures.
The funds will support Escala's commercial operations expansion in the U.S., preparations for European market entry pending CE approval, and international growth through a new distribution agreement covering Southeast Asia. The company currently maintains a direct sales team in the U.S. and is positioned for significant growth in 2025 and beyond.
Arcuro Medical has received FDA 510(k) clearance for its new SuperBall-RC™ system designed for rotator cuff repair procedures. The technology addresses the significant challenge of rotator cuff re-tear rates, which affect 20%-40% of patients over 50 years old. The system builds upon Arcuro's established SuperBall platform, which has been successfully used in over 5,000 meniscus repairs.
The device aims to simplify the fixation of rotator cuff augmentation grafts, offering surgeons an improved solution for enhanced healing outcomes. Following this regulatory milestone, Arcuro plans a user release in Q2 2025, with a full market launch scheduled for the second half of 2025 - ahead of their original timeline due to expedited FDA clearance.
Limaca Medical's Precision-GI™ endoscopic biopsy device has been granted transitional pass-through (TPT) payment by CMS, effective January 1, 2025, for up to three years. The device, which received FDA Breakthrough Device Designation in 2022 and FDA clearance in August 2023, is designed to improve biopsy results for gastrointestinal cancers. The motorized, automated rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass, enhancing diagnostic efficiency. The TPT program will support broader patient access by providing additional payments to hospitals to cover adoption costs. The device began its U.S. market entry in September 2024.
Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.
Dasyo, a pioneer in noninvasive medical aesthetics technologies, has appointed Domenic (Dom) Serafino as Executive Board Chair. Serafino brings extensive industry experience, having co-founded and led Venus Concept Inc. to over $100 million in annual revenues. He was also instrumental in Syneron Medical Corp's successful IPO. Dasyo, funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), is developing a groundbreaking non-surgical breast lift product using proprietary technology for noninvasive directional skin tightening. This appointment is expected to significantly enhance Dasyo's strategic direction and growth potential in the aesthetics medical device sector.
Ceretrieve announced successful results of its multicenter, single-arm study for its aspiration catheter, aimed at treating acute ischemic stroke (AIS) caused by large vessel occlusion (LVO).
The study involved 20 patients and achieved 100% Complete/Near-Complete Perfusion with the Gen 2 device, far exceeding the 30%-40% rate of current gold-standard devices.
Ceretrieve's device allows single-pass clot removal and full blood flow restoration, ensuring high safety by minimizing the risk of clot fragments moving further into the brain.
The technology demonstrated superior performance compared to existing devices, highlighting its potential to significantly improve post-stroke patient outcomes.
ZygoFix, a Trendlines portfolio company, has received FDA clearance for its zLOCK Lumbar Facet Fixation System, revolutionizing spinal fusion surgery. The system, backed by strong clinical evidence, offers a minimally invasive procedure with long-term pain reduction benefits. With CE certification and successful clinical utilization, ZygoFix is poised to make a significant impact in the US market.